Targeting the interleukin-1 pathway in patients with hematological disorders
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Interleukin-1α (IL-1α) and IL-1β are potent inflammatory cytokines that activate local and systemic inflammatory processes and are involved in protective immune responses against infections. However, their dysregulated production and signaling can aggravate tissue damage during infection, inflammatory diseases, and chemotherapy-induced intestinal mucositis. Additionally, cytokines of the IL-1 family play an important role in homeostatic as well as “emergency” hematopoiesis and are involved in the pathogenesis of several myeloid and lymphoid hematological malignancies. In the pathogenesis of intestinal mucositis and graft-versus-host disease (GVHD), these cytokines are considered pivotal during the initiation as well as propagation phase, and insights from animal studies suggest that targeting the IL-1 pathway can significantly ameliorate mucositis and GVHD. Moreover, IL-1α and IL-1β might prove to be valuable targets for both prevention and treatment of cancer and cancer therapy–related complications, and the first clinical studies have already been performed in the setting of hematological malignancies. In this review, we will discuss the role of cytokines of the IL-1 family in hematological malignancies, chemotherapy-induced intestinal mucositis, and GVHD, and speculate on possibilities of therapeutically targeting the IL-1 pathway in hematological patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“Negative impact on immune-mediated anticancer responses: Several cytotoxic drugs, such as anthracyclines and oxaliplatin, as well as radiotherapy, are able to induce immunogenic cell death, which contributes to their anticancer effects.(108,109) Moreover, cyclophosphamide has been described to elicit a systemic antica…”
BackgroundClonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945 · cited 3×
“It plays a role in allergic type 2 immunity, maintenance of epithelial barrier functions and tissue repair.(17,22)”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712 · cited 1×
“Negative impact on immune-mediated anticancer responses: Several cytotoxic drugs, such as anthracyclines and oxaliplatin, as well as radiotherapy, are able to induce immunogenic cell death, which contributes to their anticancer effects.(108,109) Moreover, cyclophosphamide has been described to elicit a systemic antica…”
BackgroundForging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Manz, M. G., & Boettcher, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3660 · Cited by 855
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Pietras, E. M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L. V., Zhang, S., Lakshminarasimhan, R., Chin, C. P., Techner, J.-M., Will, B., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3346 · Cited by 689 · cited 1×
“IL-1/IL-17/G-CSF pathway and myeloid cell proliferation: IL-1β is crucial for homeostatic as well as ‘emergency’ hematopoiesis.(3,4,53) It induces the production and secretion of IL-17 and subsequently of granulocyte colony-stimulating factor (G-CSF), which drives proliferation of hematopoietic stem cells and myeloid…”
BackgroundOrjalo, A. V., Bhaumik, D., Gengler, B. K., Scott, G. K., & Campisi, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905299106 · Cited by 654
Interleukin-33 in tissue homeostasis, injury, and inflammation
Molofsky, A. B., Savage, A. K., & Locksley, R. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.006 · Cited by 638
Cited by
IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice
Kovtonyuk, L. V., Caiado, F., Garcia-Martin, S., Manz, E.-M., Helbling, P., Takizawa, H., Boettcher, S., Al-Shahrour, F., Nombela-Arrieta, C., Slack, E., et al. (2022) · Blood · doi:10.1182/blood.2021011570 · Cited by 166
PU.1 is required to restrain myelopoiesis during chronic inflammatory stress
Chavez, J. S., Rabe, J. L., Niño, K. E., Wells, H. H., Gessner, R. L., Mills, T. S., Hernandez, G., & Pietras, E. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1204160 · Cited by 14
“IL-1 signaling is also linked to somatic evolutionary processes that give rise to myeloid malignancy (Barreyro et al., 2012; Pietras et al., 2016; de Mooij et al., 2017; Caiado et al., 2021; Burns et al., 2022; Caiado et al., 2022).”
Background
Metadata
- Authors
- de Mooij, C. E. M., Netea, M. G., van der Velden, W. J. F. M., & Blijlevens, N. M. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-06-15
- Volume
- 129
- Issue
- 24
- Pages
- 3155-3164
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2612502272
- Cited by
- 78
- References
- 21
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the interleukin-1 pathway in patients with hematological disorders. https://app.cochat.ai/papers/10.1182/blood-2016-12-754994
- The paper
- de Mooij, C. E. M., Netea, M. G., van der Velden, W. J. F. M., & Blijlevens, N. M. A. (2017). Targeting the interleukin-1 pathway in patients with hematological disorders. Blood. https://doi.org/10.1182/blood-2016-12-754994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.